Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature

Edward K. Agyare, Sarah R. Leonard, Geoffry L. Curran, Caroline C. Yu, Val Lowe, Anant K. Paravastu, Joseph F. Poduslo, Karunya K. Kandimalla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy (CAA), which occurs in about 80% of Alzheimer's disease (AD) patients. While Aβ42 predominates parenchymal amyloid plaques in AD brain, Aβ40 is prevalent in the cerebrovascular amyloid. Dutch mutation of Aβ40 (E22Q) promotes aggressive cerebrovascular accumulation and leads to severe CAA in the mutation carriers; knowledge of how DutchAβ40 drives this process more efficiently than Aβ40 could reveal various pathophysiological events that promote CAA. In this study we have demonstrated that DutchAβ40 shows preferential accumulation in the blood-brain-barrier (BBB) endothelial cells due to its inefficient blood-to-brain transcytosis. Consequently, DutchAβ40 establishes a permeation barrier in the BBB endothelium, prevents its own clearance from the brain, and promotes the formation of amyloid deposits in the cerebral microvessels. The BBB endothelial accumulation of native Aβ40 is not robust enough to exercise such a significant impact on its brain clearance. Hence, the cerebrovascular accumulation of Aβ40 is slow and may require other copathologies to precipitate into CAA. In conclusion, the magnitude of Aβ accumulation in the BBB endothelial cells is a critical factor that promotes CAA; hence, clearing vascular endothelium of Aβ proteins may halt or even reverse CAA.

Original languageEnglish (US)
Pages (from-to)1557-1565
Number of pages9
JournalMolecular Pharmaceutics
Volume10
Issue number5
DOIs
StatePublished - May 6 2013

Fingerprint

Cerebral Amyloid Angiopathy
Amyloidogenic Proteins
Blood-Brain Barrier
Alzheimer Disease
Brain
Amyloid Plaques
Amyloid
Endothelial Cells
Transcytosis
Mutation
Vascular Endothelium
Microvessels
Endothelium
Exercise

Keywords

  • Alzheimer's disease
  • amyloid beta proteins
  • blood-brain barrier
  • cerebral amyloid angiopathy
  • transcytosis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature. / Agyare, Edward K.; Leonard, Sarah R.; Curran, Geoffry L.; Yu, Caroline C.; Lowe, Val; Paravastu, Anant K.; Poduslo, Joseph F.; Kandimalla, Karunya K.

In: Molecular Pharmaceutics, Vol. 10, No. 5, 06.05.2013, p. 1557-1565.

Research output: Contribution to journalArticle

Agyare, Edward K. ; Leonard, Sarah R. ; Curran, Geoffry L. ; Yu, Caroline C. ; Lowe, Val ; Paravastu, Anant K. ; Poduslo, Joseph F. ; Kandimalla, Karunya K. / Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature. In: Molecular Pharmaceutics. 2013 ; Vol. 10, No. 5. pp. 1557-1565.
@article{21fdc1b1101b4a7eabedb4ae266c0854,
title = "Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature",
abstract = "Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy (CAA), which occurs in about 80{\%} of Alzheimer's disease (AD) patients. While Aβ42 predominates parenchymal amyloid plaques in AD brain, Aβ40 is prevalent in the cerebrovascular amyloid. Dutch mutation of Aβ40 (E22Q) promotes aggressive cerebrovascular accumulation and leads to severe CAA in the mutation carriers; knowledge of how DutchAβ40 drives this process more efficiently than Aβ40 could reveal various pathophysiological events that promote CAA. In this study we have demonstrated that DutchAβ40 shows preferential accumulation in the blood-brain-barrier (BBB) endothelial cells due to its inefficient blood-to-brain transcytosis. Consequently, DutchAβ40 establishes a permeation barrier in the BBB endothelium, prevents its own clearance from the brain, and promotes the formation of amyloid deposits in the cerebral microvessels. The BBB endothelial accumulation of native Aβ40 is not robust enough to exercise such a significant impact on its brain clearance. Hence, the cerebrovascular accumulation of Aβ40 is slow and may require other copathologies to precipitate into CAA. In conclusion, the magnitude of Aβ accumulation in the BBB endothelial cells is a critical factor that promotes CAA; hence, clearing vascular endothelium of Aβ proteins may halt or even reverse CAA.",
keywords = "Alzheimer's disease, amyloid beta proteins, blood-brain barrier, cerebral amyloid angiopathy, transcytosis",
author = "Agyare, {Edward K.} and Leonard, {Sarah R.} and Curran, {Geoffry L.} and Yu, {Caroline C.} and Val Lowe and Paravastu, {Anant K.} and Poduslo, {Joseph F.} and Kandimalla, {Karunya K.}",
year = "2013",
month = "5",
day = "6",
doi = "10.1021/mp300352c",
language = "English (US)",
volume = "10",
pages = "1557--1565",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature

AU - Agyare, Edward K.

AU - Leonard, Sarah R.

AU - Curran, Geoffry L.

AU - Yu, Caroline C.

AU - Lowe, Val

AU - Paravastu, Anant K.

AU - Poduslo, Joseph F.

AU - Kandimalla, Karunya K.

PY - 2013/5/6

Y1 - 2013/5/6

N2 - Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy (CAA), which occurs in about 80% of Alzheimer's disease (AD) patients. While Aβ42 predominates parenchymal amyloid plaques in AD brain, Aβ40 is prevalent in the cerebrovascular amyloid. Dutch mutation of Aβ40 (E22Q) promotes aggressive cerebrovascular accumulation and leads to severe CAA in the mutation carriers; knowledge of how DutchAβ40 drives this process more efficiently than Aβ40 could reveal various pathophysiological events that promote CAA. In this study we have demonstrated that DutchAβ40 shows preferential accumulation in the blood-brain-barrier (BBB) endothelial cells due to its inefficient blood-to-brain transcytosis. Consequently, DutchAβ40 establishes a permeation barrier in the BBB endothelium, prevents its own clearance from the brain, and promotes the formation of amyloid deposits in the cerebral microvessels. The BBB endothelial accumulation of native Aβ40 is not robust enough to exercise such a significant impact on its brain clearance. Hence, the cerebrovascular accumulation of Aβ40 is slow and may require other copathologies to precipitate into CAA. In conclusion, the magnitude of Aβ accumulation in the BBB endothelial cells is a critical factor that promotes CAA; hence, clearing vascular endothelium of Aβ proteins may halt or even reverse CAA.

AB - Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy (CAA), which occurs in about 80% of Alzheimer's disease (AD) patients. While Aβ42 predominates parenchymal amyloid plaques in AD brain, Aβ40 is prevalent in the cerebrovascular amyloid. Dutch mutation of Aβ40 (E22Q) promotes aggressive cerebrovascular accumulation and leads to severe CAA in the mutation carriers; knowledge of how DutchAβ40 drives this process more efficiently than Aβ40 could reveal various pathophysiological events that promote CAA. In this study we have demonstrated that DutchAβ40 shows preferential accumulation in the blood-brain-barrier (BBB) endothelial cells due to its inefficient blood-to-brain transcytosis. Consequently, DutchAβ40 establishes a permeation barrier in the BBB endothelium, prevents its own clearance from the brain, and promotes the formation of amyloid deposits in the cerebral microvessels. The BBB endothelial accumulation of native Aβ40 is not robust enough to exercise such a significant impact on its brain clearance. Hence, the cerebrovascular accumulation of Aβ40 is slow and may require other copathologies to precipitate into CAA. In conclusion, the magnitude of Aβ accumulation in the BBB endothelial cells is a critical factor that promotes CAA; hence, clearing vascular endothelium of Aβ proteins may halt or even reverse CAA.

KW - Alzheimer's disease

KW - amyloid beta proteins

KW - blood-brain barrier

KW - cerebral amyloid angiopathy

KW - transcytosis

UR - http://www.scopus.com/inward/record.url?scp=84877280219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877280219&partnerID=8YFLogxK

U2 - 10.1021/mp300352c

DO - 10.1021/mp300352c

M3 - Article

C2 - 23249146

AN - SCOPUS:84877280219

VL - 10

SP - 1557

EP - 1565

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 5

ER -